BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Therapeutic Court Association of Washington and Washington Association of Drug Courts - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://tcaofwa.org
X-WR-CALDESC:Events for Therapeutic Court Association of Washington and Washington Association of Drug Courts
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260402T080000
DTEND;TZID=America/Los_Angeles:20260402T170000
DTSTAMP:20260511T030447
CREATED:20260403T004148Z
LAST-MODIFIED:20260403T004148Z
UID:9523-1775116800-1775149200@tcaofwa.org
SUMMARY:Ask the Expert: Exploring Metabolic Psychiatry
DESCRIPTION:Brought to you by NAMI:  \nThursday\, April 9\, 2026 | 4:00 – 5:30 p.m. ET \nWant to learn more about the cutting-edge science of metabolic psychiatry?\nThis webinar will explore metabolic therapies for psychiatric conditions from both a clinical and lived experience perspective.\nDr. Calogero (Carlo) Longhitano\, psychiatrist and Associate Professor of Psychiatry at James Cook University (JCU)\, will share his insights on the potential of ketogenic therapy as both a clinician and researcher. He is co-investigator of JCU’s randomized controlled trial comparing a ketogenic diet with a standard diet in adults with bipolar disorder and schizophrenia.\nHannah Warren will share her experience of putting symptoms of bipolar I disorder into remission using metabolic therapies\, including a ketogenic diet. She will also discuss testimonials from additional individuals with a wide variety of diagnoses. \nYou’ll hear more about:\n•	The potential for meaningful improvements in both mental and physical health through ketogenic therapy\n•	How to mitigate risks and access the growing number of resources available to help individuals explore this promising intervention safely\n•	How a grassroots movement is emerging to expand awareness of an access to metabolic therapies for psychiatric conditions\nWhether you’re seeking answers for yourself\, a loved one\, or your patients\, this session will provide cutting-edge information grounded in the latest research and lived experience. \nReserve your spot today and submit your questions for our presenters through the registration form!  https://nami-org.zoom.us/webinar/register/WN_jGyO45I4TI2jN3-bOvRp6g#/registration \nGuest Prsenters:\nDr. Carlo Longhitano\, MD \nAssociate Professor of Psychiatry\nJames Cook University\, Australia \nCarlo Longhitano is the Associate Professor of Psychiatry at James Cook University medical school and a psychiatrist at North Queensland Forensic MH Services. He obtained his MD in 1999 (Italy) before completing his psychiatric residency in Oxford and London (UK) where he held senior positions before moving to Townsville\, Australia\, in 2018. Carlo is completing a PhD project on the effects of nutritional interventions in psychosis. He is the co-investigator with Prof Zoltan Sarnyai at JCU’s randomized clinical trial of ketogenic metabolic therapy vs standard diet in adults with bipolar disorder and schizophrenia. The project is supported and funded by the US-based Baszucki Brain Research Foundation. Additionally\, Carlo is a member of the forensic faculty of the RANZCP\, a board member at Margaret Roderick Centre for MH Research and a scientific advisor to the Australasian Metabolic Health Society. He is the author of several peer-reviewed articles and two textbook chapters.  \nHannah Warren \nLived Experience Advocate\, Communications & Advocacy Manager\nMetabolic Mind \nHannah serves as Communications and Advocacy Manager at Baszucki Group and Metabolic Mind\, where she works to advance awareness of metabolic psychiatry. Following her remission from bipolar I disorder through ketogenic therapy in 2021\, she dedicated herself to sharing the growing scientific foundation of metabolic therapies and promoting their potential as first-line interventions.\nShe is cofounder of Metabolic Collective\, a nonprofit organization building grassroots communities to expand awareness of and access to metabolic therapies for psychiatric and neurological conditions.\nHannah has spent much of her career in the nonprofit sector\, most recently serving as Marketing and Development Director at Serenity Hospice and Home.\nShe holds an M.A. in Fashion Entrepreneurship from the London College of Fashion and a B.A. in South Asian Studies and Linguistics from the School of Oriental and African Studies\, University of London. She is currently writing a book titled Radiant Beast: The Mitochondrial Pathway. \n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/ask-the-expert-exploring-metabolic-psychiatry/
LOCATION:Online
CATEGORIES:Advocacy,Behavioral Health,Office Hours,Treatment
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/04/Screenshot-2026-04-02-173824.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260403T090000
DTEND;TZID=America/Los_Angeles:20260403T100000
DTSTAMP:20260511T030447
CREATED:20260327T004538Z
LAST-MODIFIED:20260327T004538Z
UID:9260-1775206800-1775210400@tcaofwa.org
SUMMARY:Evidence-Based Treatment for Stimulant Use Disorders Among Populations at Elevated Risk for HIV
DESCRIPTION:Brought to you by Opioid Research Network \nEvidence-Based Treatment for Stimulant Use Disorders Among Populations at Elevated Risk for HIV \nFriday April 3\, 2026 12:00 – 1:00 PM ET \nORN Partner Organization Sponsor: National Alliance for HIV Education and Workforce Development (NAHEWD) \nThis lecture will review safety optimization strategies and evidence-based treatments for stimulant use disorders\, including special attention to populations at elevated risk of HIV. The session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series is highlighting various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. \nThis session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series will highlight various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. This lecture will review safety optimization strategies and evidence-based treatments for stimulant use disorders\, including special attention to populations at elevated risk of HIV. By the end of the presentation\, participants will be able to: 1. Contextualize stimulant use disorder and substance use among populations at elevated risk for HIV using epidemiology and syndemic theory. 2. Apply safety optimization techniques to support the wellness of people who use stimulants. 3. Translate clinical research on treatments for stimulants into therapeutic prescribing practices. \nRegister Here: Webinar Registration – Zoom
URL:https://tcaofwa.org/event/evidence-based-treatment-for-stimulant-use-disorders-among-populations-at-elevated-risk-for-hiv/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-174430.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260413T110000
DTEND;TZID=America/Los_Angeles:20260413T120000
DTSTAMP:20260511T030447
CREATED:20260327T005846Z
LAST-MODIFIED:20260327T005846Z
UID:9270-1776078000-1776081600@tcaofwa.org
SUMMARY:Medetomidine Impacts on Clinical Management and Systems of Care
DESCRIPTION:ORN Partner Organization Sponsor: American Osteopathic Academy of Addiction Medicine (AOAAM) \nWednesday May 13\, 2026 5:00 – 6:00 PM ET \nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nDescription:\n\nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation entitled will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nLearning objectives:\nAt the conclusion of this seminar\, attendees should be able to: \n\nDescribe the emergence of medetomidine as an illicit drug adulterant and its impact on overdose toxicity and withdrawal presentations.\nRecognize the clinical features of medetomidine toxicity and differentiate medetomidine withdrawal from withdrawal syndromes.\nApply evidence-informed strategies for early\, aggressive management of medetomidine withdrawal\, including the use of alpha-2 agonists and antiemetic therapies.\nIdentify system-level challenges posed by medetomidine and outline approaches to multidisciplinary coordination.\n\nWhat is ORN\n\n\nHelp is here! The Opioid Response Network (ORN) is your resource for no-cost education\, training and consultation to enhance efforts addressing opioid and stimulant use disorders.\nORN has consultants in every state and territory to deploy across prevention\, treatment\, recovery and harm reduction.\nShare your needs via the “Submit a Request” form at www.OpioidResponseNetwork.org. Within one business day\, your regional point person will be in touch to learn more.\n\nSpeaker: \nMichael Lynch\, MD \n\nDr. Michael Lynch is an associate professor of Emergency Medicine\, Toxicology\, and Addiction Medicine at the University of Pittsburgh where he works clinically in several UPMC hospitals. He is currently Senior Medical Director for Quality and Substance Use Disorder Services at UPMC Health Plan. He previously served as the first Medical Director of the PA Department of Drug and Alcohol Programs and was Medical Director of the Pittsburgh Poison Center for 10 years. Dr. Lynch is the founder and director of the UPMC Medical Toxicology Telemedicine Bridge Clinic. \nDISCLAIMER\nACCREDITATION:\nIn support of improving patient care\, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nDISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:\nAll conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships\, or the lack thereof\, will be provided to learners.\n\nFunding:\nFunding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names\, commercial practices\, or organizations imply endorsement by the U.S. Government.\n\n\n\nRegister Here: ORN Spring 2026: Medetomidine Impacts on Clinical Management and Systems of Care\n\n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/medetomidine-impacts-on-clinical-management-and-systems-of-care/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-175327.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260423T000000
DTEND;TZID=America/Los_Angeles:20260424T235959
DTSTAMP:20260511T030447
CREATED:20260311T050957Z
LAST-MODIFIED:20260311T050957Z
UID:9007-1776902400-1777075199@tcaofwa.org
SUMMARY:TeleBehavioral Health Summit: Artificial Intelligence in Behavioral Health
DESCRIPTION:Brought to you by HCA/University of Washington \nThe Behavioral Health Institute is pleased to offer the 2026 TeleBehavioral Health Summit\, generously funded by the Washington State Legislature\, in partnership with the Northwest Regional Telehealth Resource Center (NRTRC). \nThis two-day summit brings together national experts\, clinicians\, policymakers\, and behavioral health leaders to explore the practical\, ethical\, and regulatory dimensions of AI in mental health and substance use care. \nDesigned for clinicians\, peer professionals\, administrators\, and system leaders\, the Summit focuses on real-world applications of AI — supporting safe\, effective\, and responsible integration into behavioral health practice. \nJoin us for timely\, frontline-focused education on what’s here now\, what’s emerging\, and how to stay grounded in an evolving digital care landscape. \nCredit Offered: AMA PRA Category 1 Credit™; Nursing contact hours; Interprofessional Continuing Education (IPCE). Full accreditation information can be found at the BHI Continuing Education & Accreditation webpage. \nDates and times\n\nThursday\, April 23: 9:30 a.m. – 3:30 p.m.\nFriday\, April 24: 10 a.m. – 3:45 p.m.\n\nRegister Here: \nAirmeet: 2026 TeleBehavioral Health Summit
URL:https://tcaofwa.org/event/telebehavioral-health-summit-artificial-intelligence-in-behavioral-health/
LOCATION:Online
CATEGORIES:Conference,Treatment
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-10-220852.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260427T000000
DTEND;TZID=America/Los_Angeles:20260430T235959
DTSTAMP:20260511T030447
CREATED:20260307T172341Z
LAST-MODIFIED:20260307T172341Z
UID:8987-1777248000-1777593599@tcaofwa.org
SUMMARY:Western Regional Conference of Problem Gambling Awareness: Focus on the Future
DESCRIPTION:April 27-30\, 2026 | Vancouver\, WA\n\nOnline registration is open through April 20\, 2026! \nFocus on the Future is the largest and longest-standing conference on problem gambling awareness in the Pacific Northwest. Launched in 2007\, Focus on the Future brings together an incredible mixture of compelling speakers – experts from across the country and around the world – and opportunities to network and learn from colleagues in the field. It is a place where you can exchange your ideas\, experiences\, and knowledge to become a collective voice in raising awareness and developing programs and services that have the greatest positive impact. Problem gambling affects every community in our region and can cripple the lives not only of gamblers themselves\, but of their families and friends as well. \n\n\n\n\n\nHotel \n(Special Rate Deadline is April 20\, 2026) \n\n\n\n\n\nRegistration \n(Early Bird Discounts End April 10\, 2026) \n\n\n\n\n\nAgenda \n\n\n\n\n\n\nScholarships \n(Scholarship Deadline is\nApril 17\, 2026) \n\n\n\n\n\n\n\n\n\nPartners \n\n\n\n\n\nSponsors \n\n\n\nThis conference will provide valuable insights on the tools and resources available for effective treatment\, prevention\, community engagement\, and recovery services\, as well as offering information on trends and innovative topics in gambling and gaming that affect your work. By joining us at Focus on the Future\, you will have a prime opportunity to collaborate with and learn from some of the best in the field. You’ll no doubt leave with some new connections and partnerships that may lead to enhanced and innovative approaches toward assisting those who are affected by problem gambling. \nThank you\, to all of you who make such an important difference for those in our region who need support and services. We have much to look forward to as we Focus on the Future and all we can accomplish working together. \n\n\n  \n  \n\nIPGGC is pending application approval/renewal for Focus on the Future 2026
URL:https://tcaofwa.org/event/western-regional-conference-of-problem-gambling-awareness-focus-on-the-future/
LOCATION:The Heathman Lodge\, 7801 NE Greenwood Drive\, Vancouver\, WA\, 98662\, United States
CATEGORIES:Advocacy,Gambling,Skill Building,Treatment
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-07-091201.png
END:VEVENT
END:VCALENDAR